Stabilization of MCL-1 by E3 ligase TRAF4 confers radioresistance

Ming Li1,2,3,4, Feng Gao1,5, Xiaoying Li4

  • 1Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, People's Republic of China.

Cell Death & Disease
|December 19, 2022
PubMed

Insights

Tumor suppressor TRAF4 (TNF receptor-associated factor 4) overexpression enhances oral cancer radiosensitivity by stabilizing MCL-1 via Akt signaling. Targeting TRAF4 may improve radiotherapy outcomes for oral squamous cell carcinoma (OSCC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • TNF receptor-associated factor 4 (TRAF4), an E3 ligase, is linked to poor prognosis in cancers.
  • The role of TRAF4 in oral squamous cell carcinoma (OSCC) carcinogenesis and radiosensitivity is not well understood.

Purpose of the Study:

  • To investigate the function of TRAF4 in OSCC radiosensitivity.
  • To elucidate the molecular mechanisms by which TRAF4 influences radiosensitivity in OSCC.

Main Methods:

  • Analysis of TRAF4 expression in OSCC tissues.
  • TRAF4 depletion and knockout experiments in OSCC cells.
  • Investigation of TRAF4-Akt-MCL-1 signaling pathway interactions.
  • Assessment of radiosensitivity in vitro and in vivo.

Main Results:

  • TRAF4 is upregulated in OSCC and enhances radioresistance.
  • TRAF4 depletion reduces OSCC cell proliferation, colony formation, and tumor growth.
  • TRAF4 stabilizes MCL-1 through Akt-mediated ubiquitination, promoting radioresistance.
  • TRAF4 expression correlates with MCL-1 in tumor tissues.

Conclusions:

  • TRAF4 confers radioresistance in OSCC by stabilizing MCL-1 via Akt signaling.
  • Targeting TRAF4 presents a potential strategy to overcome radioresistance in OSCC.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K